+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
BROOKS

Brooks Laboratories Share Price

 

 

Brooks Laboratories live price: ₹73.55. It opened at ₹79 vs previous close ₹77; intraday high/low: ₹79/₹73. The 50 & 200 DMA stand at ₹63.85/₹81.49.

Brooks Laboratories Performance

  • Today's Low
  • ₹73
  • Today's High
  • ₹79
  • 52 Week Low
  • ₹36
  • 52 Week High
  • ₹164
  • Open Price₹79
  • Previous Close₹77
  • Volume28,956
  • 50 DMA₹63.85
  • 100 DMA₹67.53
  • 200 DMA₹81.49

Brooks Laboratories Chart

Investment Returns

  • Over 1 Month + 24.18%
  • Over 3 Month + 57.23%
  • Over 6 Month -14.78%
  • Over 1 Year -50.97%

Smart Investing Starts Here Start SIP with Brooks Laboratories for Steady Growth!

Invest Now

Brooks Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 8.8
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 217
  • P/B Ratio
  • 1.8
  • Average True Range
  • 3.54
  • EPS
  • 8.35
  • Dividend Yield
  • 0
  • MACD Signal
  • 3.09
  • RSI
  • 64.61
  • MFI
  • 88.87

Latest Stock News Updates

Brooks Labs Consolidated June 2023 Net Sales at Rs 15.70 crore, down 8.3% Y-o-Y

Brooks Labs Consolidated March 2023 Net Sales at Rs 12.61 crore, down 55.68% Y-o-Y

Brooks Labs Standalone December 2022 Net Sales at Rs 12.00 crore, down 32.07% Y-o-Y

Brooks Laboratories Financials

Brooks Laboratories Technicals

EMA & SMA

Current Price
₹73.55
-3.25 (-4.23%)
pointer
  • Bearish Moving Average 2
  • Bullish Moving Average 14
  • 20 Day
  • ₹67.40
  • 50 Day
  • ₹63.80
  • 100 Day
  • ₹67.50
  • 200 Day
  • ₹81.50

Resistance and Support

75.17 Pivot Speed
  • R3 83.42
  • R2 81.21
  • R1 77.38
  • S1 71.34
  • S2 69.13
  • S3 65.30

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Brooks Laboratories has an operating revenue of Rs. 85.74 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of 7% is okay, ROE of 20% is exceptional. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and around 19% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 63 which is a FAIR score but needs to improve its earnings, a RS Rating of 48 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 44 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Brooks Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-29 Quarterly Results
2026-02-06 Quarterly Results
2025-11-14 Quarterly Results
2025-08-13 Quarterly Results
2025-05-28 Audited Results

Brooks Laboratories Shareholding Pattern

52.62%
9.9%
0%
0.17%
0%
31.56%
5.75%

Brooks Laboratories FAQs

Brooks Laboratories share price is ₹73 As on 27 June, 2026 | 11:01

The Market Cap of Brooks Laboratories is ₹216.7 Cr As on 27 June, 2026 | 11:01

The P/E ratio of Brooks Laboratories is 8.8 As on 27 June, 2026 | 11:01

The PB ratio of Brooks Laboratories is 1.8 As on 27 June, 2026 | 11:01

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23